The single financial pane of truth — P&L, quality of earnings, profitability, FP&A and line-of-business economics.
Combined ratio 112% means the book runs a ~₹471 Cr underwriting loss — the company stays profitable only because ₹598 Cr of investment income lifts it to ₹94 Cr PAT (down ~30%). Bending the combined ratio to 110% is worth ≈ ₹75 Cr of underwriting result; health pricing and motor-OD discipline are the levers.
3 of 8 headline metrics improving vs prior · still off target: Gross Written Premium (GWP) ₹5,548 Cr vs ₹6,100 Cr, GWP Growth (YoY) 10.9% vs 12.0%, Loss Ratio (Net Claims / NEP) 79.0% vs 75.0%
Drive the turnaround to <110%: health pricing, motor-OD discipline, EOM cap & fraud control.
FY25 combined ratio worsened to 112% (from 106%) as net incurred claims jumped +23%; the ~₹471 Cr underwriting loss is only covered by investment income.
At 112% the book runs a ₹471 Cr underwriting loss; each combined-ratio point on ₹3,753 Cr of net earned premium ≈ ₹38 Cr. Health (~99% loss ratio) is the marquee problem.
Book not yet retaining above par — renewals & cross-sell must lift it.
Book not yet retaining above par — renewals & cross-sell must lift it.
How ₹5,548 Cr of gross written premium converts to ₹94 Cr profit after tax — an underwriting loss offset by investment income.
| Gross Written Premium | ₹5,548 Cr | +10.9% YoY |
| Net Earned Premium | ₹3,753 Cr | after reinsurance |
| Net Incurred Claims | (₹2,961 Cr) | loss ratio 79% |
| Commissions & mgmt expenses | (₹1,263 Cr) | comm 15% + EOM 30% |
| Underwriting result | (₹471 Cr) | combined ratio 112% |
| Investment income | ₹598 Cr | yield 7.59% |
| Profit after tax | ₹94 Cr | down ~30% YoY |
The honest walk: net earned premium less claims, commissions & expenses (a ~₹471 Cr underwriting loss), offset by investment income to a positive PAT.
FY24 ₹133 Cr → FY25 ₹94 Cr: premium growth & lower commissions vs. the net claims-inflation drag (Health ~99% loss ratio + Motor OD) and management-expense / EOM pressure.
Reserving & forecast discipline, combined-ratio turnaround savings, and premium productivity.
Margin build and cross-sell capture by line as each book grew.
| Product line | Since | GWP | In-force | Margin % | Cross-sell % | Status |
|---|---|---|---|---|---|---|
| Motor — Private Car & Two-Wheeler | 2007 | ₹1,440 Cr | ₹1,250 Cr | 8→32 | 80% | Integrated |
| Commercial Fire, Marine & Engineering | 2007 | ₹900 Cr | ₹487 Cr | 6→14 | 62% | In progress |
| Motor — Commercial Vehicle | 2007 | ₹446 Cr | ₹360 Cr | 5→22 | 70% | Integrated |
| Group Health & Corporate | 2009 | ₹998 Cr | ₹700 Cr | 3→4 | 66% | In progress |
| Health Total & Absolute (retail) | 2010 | ₹620 Cr | ₹560 Cr | 4→8 | 78% | In progress |
| Weather/Crop, PA & Rural (Alpa Bima) | 2012 | ₹700 Cr | ₹300 Cr | 10→20 | 55% | In progress |
| Health Vital / PowHer (new launches) | 2024 | ₹240 Cr | ₹190 Cr | 2→5 | 60% | In progress |
One click into the owning view — each reads the same live governed dataset.
CEO brief — wins, red flags, top actions.
Open →Pull the value levers — bull / base / bear on combined ratio & PAT.
Forecast →Prove the P&L ties out — identity tests on the numbers.
Verify →A complete board strategy deck from live data.
Generate →